Skip to main content

Share story

Science

Dr. Christine Broadbridge Highlights Connecticut's Quantum Future on "Where We Live"

Dr. Christine Broadbridge Highlights Connecticut's Quantum Future on "Where We Live" Image: Primary
Dr. Christine Broadbridge appeared on Connecticut Public Radio's "Where We Live" to address the state's growing role in the quantum economy. The Feb. 10 program featured her description of Quantum 2.0 moving from theory to application. Broadbridge is a professor of physics and executive director of research and innovation at Southern Connecticut State University. She also founded the Connecticut State Colleges and Universities Center for Quantum and Nanotechnology. Student engagement and research access served as a main theme. Broadbridge said most people believe research requires a Ph.D. She added that the goal is to show people they can participate earlier. Hands-on involvement in new knowledge and technology helps students see themselves contributing to science and technology work, she said. The appearance preceded Southern's spring semester ribbon-cutting and student research showcase for the renewed center. The center's expanded mission supports Connecticut's leadership in quantum and advanced materials innovation.
Sources
Published by Tech & Business, a media brand covering technology and business. This story was sourced from Southern Connecticut State University and reviewed by the T&B editorial agent team.
Back to Newswire
Keep reading
Full wire
Capital
Capital

Nominal raises $240 million at a $3 billion valuation

Nominal has raised $240 million at a $3 billion valuation, triple its valuation in a funding round earlier this year, Bloomberg reports. The startup builds software to make manufacturing more efficient.

Capital Products
Capital Products

Onodrim raises $300M to acquire European defence and industrial suppliers

Amsterdam-based Onodrim Industries has raised $300M in a round led by Lux Capital, valuing the defence group at $1.3bn, the company said Monday. Other investors include General Catalyst, Lakestar and Altimeter. The financing follows its €40M seed round in February.

Capital
Capital

SRTD Biotech raises €31.5 million for targeted RNA therapies

SRTD Biotech has completed an oversubscribed €31.5 million seed financing to develop RNA therapies designed to act selectively inside diseased cells. Mérieux Equity Partners led the round, with NRW.BANK and Boehringer Ingelheim Venture Fund joining as co-leads.